At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Two Doses of Recombinant Human Nerve Growth Factor in Patients With Stage 2 and 3 of NK
In Brief
A Phase 2 clinical trial evaluating rhNGF 10 μg/ml, rhNGF 20 μg/ml, and 1 other intervention for Neurotrophic Keratitis and 2 related conditions. Completed, enrolled 174 participants across 34 sites in 6 countries.
Detailed Summary
This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis
Study Details
Timeline
Interventions
rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
ophthalmic solution of the same composition as the test product without rhNGF